对《基于Logit模型分析确定的与乳腺癌复发相关的预后生物标志物》的更正
Correction to: Prognostic biomarkers related to breast cancer recurrence identified based on Logit model analysis.
作者信息
Zhou Xiaoying, Xiao Chuanguang, Han Tong, Qiu Shusheng, Wang Meng, Chu Jun, Sun Weike, Li Liang, Lin Lili
机构信息
Department of Nursing, Wuxi Higher Health Vocational Technology School, Wuxi, 2140128, Jiangsu, China.
Department of Breast Thyroid Surgery, Central Hospital of Zibo, Zibo, 255036, Shandong, China.
出版信息
World J Surg Oncol. 2020 Dec 5;18(1):320. doi: 10.1186/s12957-020-02079-0.
Abstract
An amendment to this paper has been published and can be accessed via the original article.
摘要
本文的一篇修正已发表，可通过原文获取。
相似文献
1
Correction to: Prognostic biomarkers related to breast cancer recurrence identified based on Logit model analysis.
World J Surg Oncol. 2020 Dec 5;18(1):320. doi: 10.1186/s12957-020-02079-0.
2
Correction to: Circular RNA circ-ZKSCAN1 inhibits bladder cancer progression through miR-1178-3p/p21 axis and acts as a prognostic factor of recurrence.
Mol Cancer. 2020 Oct 12;19(1):148. doi: 10.1186/s12943-020-01265-8.
3
Correction to: Relationship of objectively measured physical activity and sedentary behaviour with health-related quality of life among breast cancer survivors.
Health Qual Life Outcomes. 2020 Aug 6;18(1):259. doi: 10.1186/s12955-020-01513-x.
4
Correction to: microRNA-124 inhibits bone metastasis of breast cancer by repressing Interleukin-11.
Mol Cancer. 2020 Jun 27;19(1):111. doi: 10.1186/s12943-020-01226-1.
5
Correction to: Regional disparities in the flow of access to breast cancer hospitalizations in Brazil in 2004 and 2014.
BMC Womens Health. 2020 Dec 8;20(1):270. doi: 10.1186/s12905-020-01129-9.
6
Correction to: The efficacy of etanercept as anti-breast cancer treatment is attenuated by residing macrophages.
BMC Cancer. 2020 Nov 20;20(1):1126. doi: 10.1186/s12885-020-07641-3.
7
Correction to: LINC00673 is activated by YY1 and promotes the proliferation of breast cancer cells via the miR-515-5p/MARK4/Hippo signaling pathway.
J Exp Clin Cancer Res. 2020 Aug 11;39(1):154. doi: 10.1186/s13046-020-01645-4.
8
Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
Breast Cancer Res. 2020 May 20;22(1):52. doi: 10.1186/s13058-020-01294-7.
9
Correction to: Identification of ALDH3A2 as a novel prognostic biomarker in gastric adenocarcinoma using integrated bioinformatics analysis.
BMC Cancer. 2020 Nov 24;20(1):1141. doi: 10.1186/s12885-020-07659-7.
10
Correction to: Relevance of biomarkers across different neurodegenerative diseases.
Alzheimers Res Ther. 2020 Jun 9;12(1):71. doi: 10.1186/s13195-020-00637-y.
引用本文的文献
1
The prognostic value of tumor mutational burden related 6-gene-based Risk Score in laryngeal cancer patients.
BMC Oral Health. 2022 Nov 17;22(1):510. doi: 10.1186/s12903-022-02534-2.
本文引用的文献
1
Prognostic biomarkers related to breast cancer recurrence identified based on Logit model analysis.
World J Surg Oncol. 2020 Sep 25;18(1):254. doi: 10.1186/s12957-020-02026-z.
Zotero 插件